Search
Asparaginase Erwinia chrysanthemi
go.drugbank.com/drugs/DB08886ApprovedInvestigational[L1448] L-asparaginase was first identified in 1963,[A236344] and there are different formulations of L-asparaginase, including [Asparaginase Escherichia coli] and a pegylated form of this enzyme, [Pegaspargase … Asparaginase _Erwinia chrysanthemi_ and [Asparaginase Escherichia coli] differ in their pharmacokinetic and immunogenic profiles;[L1452] thus, those who are allergic to [Asparaginase Escherichia coli] do
Synonyms: Erwinia L-asparaginase, L-asparaginase (Erwinia)L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal
go.drugbank.com/drugs/DB06124ExperimentalC-101, also called Myodur, is developed for the treatment of Duchenne’s muscular dystrophy (DMD) which is a morbid genetic disease that can lead to death in late adolescence due to accelerated skeletal … C-101 includes a carnitine carrier molecule and a leupeptin analogue, a known calpain inhibitor. Calpain is the primary protease that degrades skeletal muscle.
Acadesine
go.drugbank.com/drugs/DB04944InvestigationalAcadesine has been granted Orphan Drug Designation for B-CLL in the EU. … Acadesine (AICA-riboside) is a purine nucleoside analog with anti-ischemic properties that is currently being studied (Phase 3) for the prevention of adverse cardiovascular outcomes in patients undergoing
Alaproclate
go.drugbank.com/drugs/DB13233ExperimentalDevelopment was discontinued due to concerns over hepatotoxicity observed in animal studies. … Alaproclate has also been found to act as a non-competitive NMDA receptor antagonist although without discriminative stimulus properties similar to phencyclidine.
Cilomilast
go.drugbank.com/drugs/DB03849InvestigationalFollowing four clinical trials, the drug proved to be effective in treating COPD, however it has never been marketed due to a poor side effect profile. … It is orally active and acts as a selective Phosphodiesterase-4 inhibitor.
Ibutilide
go.drugbank.com/drugs/DB00308ApprovedIbutilide is a Class III antiarrhythmic agent available in intravenous formulations.
Levothyroxine
go.drugbank.com/drugs/DB00451ApprovedInvestigationalHowever, this is no longer recommended for the majority of patients due to several clinical concerns including limited controlled trials supporting its use. … Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland.
Mixtures: L THYROX JOD HEXAL 50/150, L THYROX JOD HEXAL 50/150Categories: UGT1A1 Substrates with a Narrow Therapeutic IndexOdesivimab
go.drugbank.com/drugs/DB15900ApprovedInvestigational[A221825] Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high … [A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection.
Tetrahydropalmatine
go.drugbank.com/drugs/DB12093InvestigationalTetrahydropalmatine is under investigation in clinical trial NCT02118610 (Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal
Categories: Dopamine D2 Receptor AntagonistsAtoltivimab
go.drugbank.com/drugs/DB15898ApprovedInvestigational[A221825] Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high … [A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection.